🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to scientists.

An International Health Concern

Gonorrhoea infections are increasing around the world, with data suggesting in excess of 82 million infections annually. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the context of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Approval

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the management of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Outcomes and Global Access

As per results detailed in a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which combines a dual-drug approach. The research enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to license and sell the drug in numerous developing nations.

Doctors on the front lines have voiced optimism. Having a easy-to-administer therapy such as this is described as a "critical tool" for gonorrhoea control. This is deemed essential to alleviate the strain of the disease for people and to prevent the spread of untreatable gonorrhoea worldwide.